^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CEBPA mutation

    i
    Other names: CEBPA, CCAAT Enhancer Binding Protein Alpha, CCAAT/Enhancer Binding Protein (C/EBP), Alpha, CCAAT/Enhancer-Binding Protein Alpha, CEBP, CCAAT/Enhancer Binding Protein Alpha, C/EBP-Alpha, C/EBP Alpha
    Entrez ID:
    1050
    Apply
    Allo HSCT Using RIC and PTCy for Hematological Diseases (NCT05805605)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    05/01/2023
    Primary completion :
    10/22/2027
    Completion :
    10/22/2028
    NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C
    |
    NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
    |
    cyclophosphamide • sirolimus • fludarabine IV
    Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (MT2015-29) (NCT03314974)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    04/16/2024
    Initiation :
    03/30/2018
    Primary completion :
    01/10/2025
    Completion :
    11/10/2025
    NPM1 • KMT2A • IKZF1 • CEBPA
    |
    NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
    |
    cyclophosphamide
    Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (NCT03674411)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Active, not recruiting
    Last update posted :
    04/10/2024
    Initiation :
    01/02/2019
    Primary completion :
    06/23/2020
    Completion :
    06/28/2024
    FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA
    |
    FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type
    |
    cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)
    Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance (NCT02756962)
    Phase 2
    Washington University School of Medicine
    Active, not recruiting
    Last update posted :
    04/02/2024
    Initiation :
    07/06/2016
    Primary completion :
    07/31/2033
    Completion :
    07/31/2033
    FLT3 • NPM1 • CEBPA
    |
    FLT3-ITD mutation • NPM1 mutation • CEBPA mutation
    |
    cytarabine • Rydapt (midostaurin)
    Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) (NCT05554393)
    Phase 2
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    03/01/2024
    Initiation :
    05/30/2024
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA
    |
    TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation • CEBPA mutation
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)
    Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCI-2018-03465) (NCT03862157)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    01/10/2024
    Initiation :
    02/27/2019
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA
    |
    NPM1 mutation • CEBPA mutation • PDGFRA rearrangement
    |
    Venclexta (venetoclax) • azacitidine • pevonedistat (MLN4924)
    Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia (NCT04415008)
    Phase 2
    wang, jianxiang
    Recruiting
    Last update posted :
    10/05/2023
    Initiation :
    06/01/2020
    Primary completion :
    06/01/2024
    Completion :
    06/01/2025
    CEBPA
    |
    CEBPA mutation
    |
    cytarabine
    TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib (NCT04173585)
    Phase 2
    University Hospital Heidelberg
    Completed
    Last update posted :
    03/27/2023
    Initiation :
    10/22/2019
    Primary completion :
    02/28/2023
    Completion :
    03/24/2023
    FLT3 • CEBPA
    |
    CEBPA mutation
    |
    cytarabine • bortezomib • Mylotarg (gemtuzumab ozogamicin)
    UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep (NCT02722668)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Active, not recruiting
    Last update posted :
    02/24/2023
    Initiation :
    05/15/2017
    Primary completion :
    02/22/2023
    Completion :
    12/01/2029
    NPM1 • KMT2A • IKZF1 • CEBPA
    |
    NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
    |
    cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous
    Double Cord Versus Haploidentical (BMT CTN 1101) (NCT01597778)
    Phase 3
    Medical College of Wisconsin
    Completed
    Last update posted :
    12/01/2021
    Initiation :
    06/01/2012
    Primary completion :
    09/11/2020
    Completion :
    09/11/2020
    NPM1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C
    |
    NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
    |
    cyclophosphamide • fludarabine IV
    Molecular Diagnostic Platform for AML (PCR-LMA) (NCT04446741)
    Phase N/A
    PETHEMA Foundation
    Recruiting
    Last update posted :
    09/06/2021
    Initiation :
    10/01/2019
    Primary completion :
    10/01/2022
    Completion :
    10/01/2022
    TP53 • FLT3 • IDH2 • NPM1 • RUNX1 • WT1 • CEBPA • PHF6 • RAD21 • BRINP3 • SMC1A
    |
    NPM1 mutation • U2AF1 mutation • CEBPA mutation
    A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias (NCT01287104)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    08/22/2019
    Initiation :
    01/29/2011
    Primary completion :
    06/28/2018
    Completion :
    06/28/2018
    FLT3 • NPM1 • CEBPA • CD4 • IL15 • IL7 • KIR2DS2
    |
    FLT3-ITD mutation • NPM1 mutation • CEBPA mutation • Chr del(5q)
    Treg Cells for AGVHD in Non-myeloablative UCB Transplant (NCT02118311)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Withdrawn
    Last update posted :
    12/02/2017
    Initiation :
    06/01/2016
    Primary completion :
    09/01/2018
    Completion :
    09/01/2018
    NPM1 • KMT2A • HLA-DRB1 • CEBPA • HLA-B
    |
    NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
    Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia (NCT01057199)
    Phase N/A
    Children's Oncology Group
    Completed
    Last update posted :
    05/07/2015
    Initiation :
    01/01/2010
    Primary completion :
    06/01/2010
    Completion :
    06/01/2010
    CEBPA • MIR34A • E2F3 • MIR194
    |
    CEBPA mutation • miR-34a overexpression • miR-34a underexpression